West Pharmaceutical Services (WST)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$339.97-0.81%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
West Pharma makes parts for injectable drugs. Sales grew 21% last year. The company expects $3.3 billion revenue in 2026. Earnings per share should be about $8.57 in 2026.
Growth could slow below 7%. Rising costs might cut profit margins. CEO change may cause uncertainty.
The price is about 35% above our fair value near $265. Analysts expect 6.5% revenue growth, but we see slower growth ahead.
Breaks if: EPS falls below $8.0 in FY26
Breaks if: Q2 EPS falls below $2.0
Breaks if: revenue falls below $3.1 billion in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on consistent revenue and earnings growth. The current thesis state is intact, supported by strong recent financial performance and management's commitment to increasing guidance.
The market appears to be pricing in a durable premium, suggesting that expectations for WST's growth are relatively high compared to its peers. The expectations gap indicates that the market anticipates continued strong performance, but the valuation is considered expensive.
Fundamentals are likely to remain strong as management is on track to meet its revenue and earnings guidance for 2026. However, there is a moderate risk due to the potential for economic headwinds affecting the healthcare sector.
The thesis hinges on WST's ability to maintain its growth trajectory and avoid cutting guidance, which could damage credibility. Additionally, the performance of sector bellwethers and broader economic indicators will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports an increase in full-year 2026 revenue guidance. Additionally, the company raised its full-year 2026 EPS guidance, reinforcing a positive outlook. There are no new threats identified that would weaken this view.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, WST's strong management execution and recent performance provide a solid foundation for the next few years. Not investment advice.